Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy Supplemental Table 1

Huggar D, Knoth RL, Copher R, and McBride A are employees of Bristol Myers Squibb and may own stock. Cao Z and Lipkin C are employees of Premier, Inc, which received payment from Bristol Myers Squibb to conduct the study. LeBlanc TW: Consultancy, Advisory board, Travel fees, Speakers Bureau, Research Funding and Patents & Royalties from AbbVie, Agios, AstraZeneca, Astellas, BMS/Celgene, Flatiron, Genentech, GSK, Jazz Pharmaceuticals, Pfizer, CareVive, Helsinn, American Cancer Society, Duke University, NINR/NIH and UpToDate. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support provided by Jane Kondejewski of SNELL Medical Communication Inc. and funded by Bristol Myers Squibb.